{"title":"内镜逆行胰胆管造影加或不加支架治疗胰胆管恶性肿瘤:一项最新荟萃分析","authors":"C. Duan, Sheng-Hui Ma","doi":"10.4172/2165-7092.S6-003","DOIUrl":null,"url":null,"abstract":"In order to assess the beneficial and harmful effects of biliary stenting via ERCP for pancreaticobiliary stricture confirmed or suspected to be malignant, prior to surgery, we identified trials through Pubmed (1950 to June 2013), Science Citation Index Expanded (1945 to June 2013), and EMBASE (1980 to June 2013). Three authors independently selected trials for inclusion and extracted data. The primary pre-surgical, post-surgical, and final outcome measures were mortality. The secondary outcomes were complications such as cholangitis, pancreatitis, bleeding, pancreatic fistula, intra-abdominal abscess, improvement in bilirubin, and quality of life. Dichotomous outcomes were reported as odds ratio (OR) with 95% confidence interval (CI) based on fixed- and random-effect models. We identified three randomized trials with 634 patients undergoing pancreatico-duodenectomy; 500 patients underwent ERCP with biliary stenting and 134 had ERCP without biliary stenting prior to surgery. Pre-surgical mortality was not significantly affected by stenting (OR 3.14, 95% CI 0.12 to 79.26), while there were significantly more complications in the stented group (OR 18.41, 95% CI 2.46 to 137.85). However, postsurgical complications were significantly less in the stented group (OR 0.31, 95% CI 0.21 to 0.48). Overall mortality (OR 1.05, 95% CI 0.46 to 1.71) and complications (OR 0.31, 95% CI 0.21 to 0.48) were not significantly different in the two groups. We could not find convincing evidence to support or refute endoscopic biliary stenting on the mortality in patients with pancreaticobiliary malignancy. Large randomized trials are needed to settle the question of pre-surgical biliary stenting.","PeriodicalId":89708,"journal":{"name":"Pancreatic disorders & therapy","volume":"23 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Endoscopic Retrograde Cholangiopancreaticography with or withoutStenting in Patients with Pancreaticobiliary Malignancy: An Updated Metaanalysis\",\"authors\":\"C. Duan, Sheng-Hui Ma\",\"doi\":\"10.4172/2165-7092.S6-003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to assess the beneficial and harmful effects of biliary stenting via ERCP for pancreaticobiliary stricture confirmed or suspected to be malignant, prior to surgery, we identified trials through Pubmed (1950 to June 2013), Science Citation Index Expanded (1945 to June 2013), and EMBASE (1980 to June 2013). Three authors independently selected trials for inclusion and extracted data. The primary pre-surgical, post-surgical, and final outcome measures were mortality. The secondary outcomes were complications such as cholangitis, pancreatitis, bleeding, pancreatic fistula, intra-abdominal abscess, improvement in bilirubin, and quality of life. Dichotomous outcomes were reported as odds ratio (OR) with 95% confidence interval (CI) based on fixed- and random-effect models. We identified three randomized trials with 634 patients undergoing pancreatico-duodenectomy; 500 patients underwent ERCP with biliary stenting and 134 had ERCP without biliary stenting prior to surgery. Pre-surgical mortality was not significantly affected by stenting (OR 3.14, 95% CI 0.12 to 79.26), while there were significantly more complications in the stented group (OR 18.41, 95% CI 2.46 to 137.85). However, postsurgical complications were significantly less in the stented group (OR 0.31, 95% CI 0.21 to 0.48). Overall mortality (OR 1.05, 95% CI 0.46 to 1.71) and complications (OR 0.31, 95% CI 0.21 to 0.48) were not significantly different in the two groups. We could not find convincing evidence to support or refute endoscopic biliary stenting on the mortality in patients with pancreaticobiliary malignancy. Large randomized trials are needed to settle the question of pre-surgical biliary stenting.\",\"PeriodicalId\":89708,\"journal\":{\"name\":\"Pancreatic disorders & therapy\",\"volume\":\"23 1\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pancreatic disorders & therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2165-7092.S6-003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatic disorders & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2165-7092.S6-003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
为了评估术前经ERCP胆道支架置入术治疗确诊或疑似恶性胰胆管狭窄的利弊,我们通过Pubmed(1950年至2013年6月)、Science Citation Index Expanded(1945年至2013年6月)和EMBASE(1980年至2013年6月)进行了试验。三位作者独立选择试验纳入并提取数据。主要的术前、术后和最终结局指标是死亡率。次要结局是并发症,如胆管炎、胰腺炎、出血、胰瘘、腹内脓肿、胆红素改善和生活质量。二分类结果报告为基于固定效应和随机效应模型的95%置信区间(CI)的比值比(OR)。我们确定了三个随机试验,634例接受胰十二指肠切除术的患者;500例患者术前行ERCP合并胆道支架置入,134例术前行ERCP未行胆道支架置入。支架置入术对术前死亡率无显著影响(OR 3.14, 95% CI 0.12 ~ 79.26),而支架置入术组的并发症明显更多(OR 18.41, 95% CI 2.46 ~ 137.85)。然而,支架组的术后并发症明显较少(OR 0.31, 95% CI 0.21 ~ 0.48)。两组患者的总死亡率(OR 1.05, 95% CI 0.46 ~ 1.71)和并发症(OR 0.31, 95% CI 0.21 ~ 0.48)无显著差异。我们无法找到令人信服的证据来支持或反驳内镜胆道支架置入对胰胆道恶性肿瘤患者死亡率的影响。需要大规模的随机试验来解决术前胆道支架置入术的问题。
Endoscopic Retrograde Cholangiopancreaticography with or withoutStenting in Patients with Pancreaticobiliary Malignancy: An Updated Metaanalysis
In order to assess the beneficial and harmful effects of biliary stenting via ERCP for pancreaticobiliary stricture confirmed or suspected to be malignant, prior to surgery, we identified trials through Pubmed (1950 to June 2013), Science Citation Index Expanded (1945 to June 2013), and EMBASE (1980 to June 2013). Three authors independently selected trials for inclusion and extracted data. The primary pre-surgical, post-surgical, and final outcome measures were mortality. The secondary outcomes were complications such as cholangitis, pancreatitis, bleeding, pancreatic fistula, intra-abdominal abscess, improvement in bilirubin, and quality of life. Dichotomous outcomes were reported as odds ratio (OR) with 95% confidence interval (CI) based on fixed- and random-effect models. We identified three randomized trials with 634 patients undergoing pancreatico-duodenectomy; 500 patients underwent ERCP with biliary stenting and 134 had ERCP without biliary stenting prior to surgery. Pre-surgical mortality was not significantly affected by stenting (OR 3.14, 95% CI 0.12 to 79.26), while there were significantly more complications in the stented group (OR 18.41, 95% CI 2.46 to 137.85). However, postsurgical complications were significantly less in the stented group (OR 0.31, 95% CI 0.21 to 0.48). Overall mortality (OR 1.05, 95% CI 0.46 to 1.71) and complications (OR 0.31, 95% CI 0.21 to 0.48) were not significantly different in the two groups. We could not find convincing evidence to support or refute endoscopic biliary stenting on the mortality in patients with pancreaticobiliary malignancy. Large randomized trials are needed to settle the question of pre-surgical biliary stenting.